Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.76 |
| ▸ | FAP | Q12884 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13983477 | 1.00 | CYP3A4 (0.76) | CYP3A4FAPCYP2D6 | |
| SCHEMBL7268779 | 1.00 | CYP3A4 (0.76) | CYP3A4FAPCYP2D6 | |
| SCHEMBL14629613 | 0.92 | CYP3A4 (0.65) | CYP3A4FAPCYP2D6 | |
| SCHEMBL15070860 | 0.90 | CYP3A4 (0.77) | CYP3A4FAPCYP2D6 | |
| SCHEMBL16638756 | 0.89 | CYP3A4 (0.76) | CYP3A4FAPCYP2D6 | |
| SCHEMBL24809663 | 0.88 | CYP3A4 (0.74) | CYP3A4FAPCYP2D6 | |
| SCHEMBL1393452 | 0.88 | CYP3A4 (0.74) | CYP3A4FAPCYP2D6 | |
| SCHEMBL1393451 | 0.88 | CYP3A4 (0.74) | CYP3A4FAPCYP2D6 | |
| SCHEMBL13360604 | 0.87 | CYP3A4 (0.58) | CYP3A4FAPCYP2D6 | |
| SCHEMBL28928317 | 0.87 | CYP3A4 (0.72) | CYP3A4FAPCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271880-A1 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED ADENINYL-PROPYLOXY PHOSPHONIC ACID OR RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-6653296-B1 | 2-phosphonomethoxypropyl derivatives of purine and pyrimidine bases | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-11-25 | — | — | US | disclosed |
| US-6479673-B1 | Antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2002-11-12 | — | — | US | disclosed |
| US-6057305-A | Antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2000-05-02 | — | — | US | disclosed |
| EP-0654037-B1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1999-05-12 | — | — | EP | disclosed |
| EP-0654037-A1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | DCTD, SAMHD1, SLC28A1 | CYP3A4 452/4885FAP 2411/4885CYP2D6 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.